Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above
NCT ID: NCT07289542
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
420 participants
INTERVENTIONAL
2025-09-15
2027-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 2: Dose level B in adults aged 50 years or above
Single injection of Dose level B of ABO1105
ABO1105
Formulation for injection
Group 3: Placebo control in adults aged 50 years or above
Single injection of placebo on Day 0
Placebo
0.9% sodium chloride (normal saline) injection
Group 1: Dose level A in adults aged 50 years or above
Single injection of Dose level A of ABO1105
ABO1105
Formulation for injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABO1105
Formulation for injection
Placebo
0.9% sodium chloride (normal saline) injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy adults ≥50 years of age, participants with underlying diseases that are stably controlled may be accepted.
3. Willing to and physically able to communicate with the investigators, understand and comply with protocol required follow-up, simple self-observation and recording using the Diary Card.
4. Male participants (and their female partners) and female participants of childbearing potential agree to continue effective contraception through 3 months following vaccination.
Exclusion Criteria
2. Acute illness or fever within 3 days prior to vaccination, or use of anti-inflammatory, anti-allergy, antibiotic, or antiviral medications due to physical discomfort.
3. Laboratory-confirmed history of RSV infection within the past 12 months, or previous vaccination with a respiratory syncytial virus vaccine.
4. Clinically significant abnormal vital signs, including but not limited to:
* Resting pulse rate \<50 beats per minute or \>100 beats per minute, participants with resting pulse between 100 to 110 without significant symptoms, such as palpitations, chest tightness, dizziness and fatigue, will be accepted.
* Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg for participants aged 50-59, or systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg for participants aged ≥60
* Body mass index (BMI) ≥30 kg/m²
5. Female participants known to be pregnant or breastfeeding, or positive pregnancy test for women of childbearing potential.
6. History of allergy to any ingredients of the investigational products, or severe allergic reactions to other vaccines, foods, or medications.
7. Use or planned use of any vaccine other than the investigational products through 30 days prior to and 30 days after vaccination in this trial.
8. Current participation in another clinical trial within 30 days prior to vaccination or planned participation before the end of this trial.
9. Clinician-diagnosed coagulation abnormalities.
10. Known medical history or diagnosis confirming the subject has a condition affecting immune system function.
11. History of myocarditis, pericarditis, or idiopathic cardiomyopathy, or presence of any condition that may increase the risk of myocarditis or pericarditis.
12. Severe or uncontrolled respiratory, cardiovascular, neurological, hematological, lymphatic, hepatic, renal, metabolic, or skeletal diseases; known severe congenital malformations; developmental disorders; or clinically diagnosed severe chronic conditions that may affect trial outcomes.
13. Current infectious period of any communicable disease, acute infection, or acute phase of chronic infection, or ongoing anti-tuberculosis treatment; or prior positive test for hepatitis B surface antigen, hepatitis C virus antibody, or Treponema pallidum antibody.
14. Past or current diagnosis of neurological or psychiatric disorders, or family history of neurological/psychiatric disorders; or other neurological conditions deemed unsuitable for trial participation by the investigator.
15. Long-term use of immunosuppressants or immunomodulators within 6 months prior to vaccination, excluding topical medications. Topical medications should not exceed recommended doses or induce systemic exposure.
16. Treatment with immunoglobulins and/or blood products or blood donation through 3 months prior to and 3 months after vaccination in this trial.
17. Suspected or known alcohol dependence or drug abuse, which may affect safety assessment or trial compliance.
18. Planned long-term or permanent relocation away from the trial site area before trial completion.
19. Investigators, sponsors, and contract research organization (CRO) staff directly involved in the trial.
20. Other circumstances deemed unsuitable for trial participation by the investigator.
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abogen Biosciences (Shanghai) Co., Ltd
INDUSTRY
Suzhou Abogen Biosciences Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baise Center For Disease Control & Prevention
Baise City, Baise, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABO1105-201
Identifier Type: -
Identifier Source: org_study_id